Lucid Air Goes 747 Miles on a Charge, Sets New Guinness World Record for EV Range
Lucid managed to push its Air Grand Touring sedan to a distance of 747 miles in July, traveling between St. Moritz, Switzerland, and Munich, Germany. Previously, the record was set at 649 miles in June 2025 by a Mercedes-Benz EQS 450+ between two Japanese cities. This new record by Lucid is especially impressive considering the route between St. Moritz and Munich includes mountain passes, secondary roads, and highway driving.
"This range record represents a significant milestone – it's yet another clear demonstration of the technological edge that defines Lucid," Eric Bach, senior vice president of product and chief engineer at Lucid, said in a statement. "Our Lucid products combine world-class vehicle efficiency with the most advanced drive units, ultra-high voltage architecture, and battery management technology available today."
Now, the standard Lucid Air Grand Touring sports an EPA range of 516 miles, meaning this Guinness World Record was accomplished with unusual tactics of some sort. Lucid turned to Umit Sabanci, a London-based entrepreneur with the Guinness title of most countries visited on a single charge in a production battery electric vehicle, for consultation on how to stretch its luxury liner's capabilities. Sabanci's experience with traversing nine countries on a single charge in a Lucid Air Grand Touring seems to have brought driving insights and efficiency tactics, but it remains unclear if the Lucid Air Grand Touring used was tweaked in any way for this latest trip.
"When I completed the nine-country journey in 2024, it was just the beginning," said Sabanci. "This new achievement takes that journey even further. I'm proud to be part of a movement that proves electric mobility isn't just the future; it's already redefining what's possible today."
Driving 749 miles without stopping generally takes at least 12 hours, a feat that we're physiologically impressed by to say the least. That distance does give you a wide range of city-to-city connections in the continental U.S. A single charge and some judicious use of the right pedal could ferry you between New York City and a Waffle House in Columbia, South Carolina in an Air Grand Touring. Similarly, it's just about the driving distance between San Diego and California's border with Oregon.
You Might Also Like
You Need a Torque Wrench in Your Toolbox
Tested: Best Car Interior Cleaners
The Man Who Signs Every Car
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Should You Think About Buying LION E-Mobility AG (ETR:LMIA) Now?
LION E-Mobility AG (ETR:LMIA), is not the largest company out there, but it led the XTRA gainers with a relatively large price hike in the past couple of weeks. While good news for shareholders, the company has traded much higher in the past year. Less-covered, small caps tend to present more of an opportunity for mispricing due to the lack of information available to the public, which can be a good thing. So, could the stock still be trading at a low price relative to its actual value? Let's take a look at LION E-Mobility's outlook and value based on the most recent financial data to see if the opportunity still exists. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. What's The Opportunity In LION E-Mobility? Good news, investors! LION E-Mobility is still a bargain right now. According to our valuation, the intrinsic value for the stock is €2.18, but it is currently trading at €1.41 on the share market, meaning that there is still an opportunity to buy now. However, given that LION E-Mobility's share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us another chance to buy in the future. This is based on its high beta, which is a good indicator for share price volatility. See our latest analysis for LION E-Mobility What kind of growth will LION E-Mobility generate? Future outlook is an important aspect when you're looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let's also take a look at the company's future expectations. LION E-Mobility's earnings over the next few years are expected to increase by 100%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value. What This Means For You Are you a shareholder? Since LMIA is currently undervalued, it may be a great time to accumulate more of your holdings in the stock. With a positive outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as capital structure to consider, which could explain the current undervaluation. Are you a potential investor? If you've been keeping an eye on LMIA for a while, now might be the time to enter the stock. Its prosperous future outlook isn't fully reflected in the current share price yet, which means it's not too late to buy LMIA. But before you make any investment decisions, consider other factors such as the strength of its balance sheet, in order to make a well-informed investment decision. If you want to dive deeper into LION E-Mobility, you'd also look into what risks it is currently facing. To that end, you should learn about the 4 warning signs we've spotted with LION E-Mobility (including 1 which is significant). If you are no longer interested in LION E-Mobility, you can use our free platform to see our list of over 50 other stocks with a high growth potential. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
27 minutes ago
- Yahoo
Is CRISPR Therapeutics' (CRSP) Rising Net Loss a Sign of Bold Investment or Growing Pressure?
CRISPR Therapeutics AG recently reported its second quarter 2025 earnings, posting revenue of US$892,000, up from US$517,000 a year ago, but recording a net loss of US$208.55 million, up from US$126.41 million in the same period last year. Despite modest revenue gains, the significantly wider loss per share suggests rising costs or investment pressures are impacting the company's financial trajectory. We'll explore how the widening net loss and higher reported expenses could reshape CRISPR Therapeutics' investment narrative going forward. The end of cancer? These 26 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. What Is CRISPR Therapeutics' Investment Narrative? To be a shareholder in CRISPR Therapeutics, you need conviction in the promise of gene-editing breakthroughs and the company's ability to translate pipeline progress into eventual commercial returns. The latest earnings report, though, spotlights a widening net loss and sharply higher operating expenses. While ongoing clinical trials and recent index inclusions remain key near-term catalysts, the size of the reported quarterly loss raises questions around cash burn and the timeline to profitability. This new financial data could shift expectations for the pace of hiring, R&D investment, or the need for additional funding, potentially affecting sentiment around CRISPR's risk profile. On balance, the recent news does not appear to instantly derail the main product development catalysts investors were tracking, but it sharpens focus on the sustainability of current spending levels and paths to revenue growth in a high-cost environment. But with losses widening, funding needs are something every investor should watch closely. CRISPR Therapeutics' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be. Exploring Other Perspectives Eighteen members of the Simply Wall St Community offer fair value estimates for CRISPR Therapeutics, ranging from US$14.57 to US$150.97 per share. As these forecasts reveal, opinions differ widely on the company's trajectory, particularly given growing expenses flagged in the latest earnings. Exploring several alternative viewpoints can help you understand the breadth of market expectations. Explore 18 other fair value estimates on CRISPR Therapeutics - why the stock might be worth less than half the current price! Build Your Own CRISPR Therapeutics Narrative Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd. A great starting point for your CRISPR Therapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision. Our free CRISPR Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CRISPR Therapeutics' overall financial health at a glance. Ready For A Different Approach? Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped: Find companies with promising cash flow potential yet trading below their fair value. Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit. These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include CRSP. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Bayern Munich open talks to sign Christopher Nkunku
Since the transfer of Nick Woltemade is still difficult to accomplish, Bayern Munich have set their sights on another one of their long-time targets: Chelsea's Christopher Nkunku. But what is new? While Bayern's interest in the French player has been there for almost the whole year, they've just now opened talks again with Nkunku, his agency and Chelsea over a possible transfer this summer. The Rekordmeister would prefer to do a loan with an option to buy, but Chelsea are pushing for a permanent sale. The interesting part: Bayern and Nkunku managed to come to an agreement on personal terms in January 2025 - and said agreement is reportedly still valid now! If the discussions between Bayern and Chelsea would now also come to a conclusion, then nothing stands in the way of the transfer. The almost finalized sale of Kingsley Coman to Al-Nassr has accelerated the negotiations for a possible replacement; Bayern are still keen on Woltemade and a deal could be struck - but they are also interested in Nkunku, who would like to join the Bavarians as well. For Chelsea, the sale of Nkunku could help them in financing the transfer of Leipzig's Xavi Simons, meaning that Bayern might be responsible for Leipzig losing their most valuable player soon.
